Literature DB >> 26863267

Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases.

Mei Lan Chen1, Mark S Sundrud.   

Abstract

Pathogenesis of the inflammatory bowel diseases (IBDs), such as ulcerative colitis (UC) and Crohn's disease (CD), involve proinflammatory changes within the microbiota, chronic immune-mediated inflammatory responses, and epithelial dysfunction. Converging data from genome-wide association studies, mouse models of IBD, and clinical trials indicate that cytokines are key effectors of both normal homeostasis and chronic inflammation in the gut. Yet many questions remain concerning the role of specific cytokines in different IBDs within distinct regions of the gut, and regarding cellular mechanisms of action. In this article, we review current and emerging concepts concerning the role of cytokines in IBD with a focus on immune regulation, T cell subsets, and potential clinical applications.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26863267      PMCID: PMC4838490          DOI: 10.1097/MIB.0000000000000714

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  171 in total

1.  ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6.

Authors:  Youn Soo Choi; Robin Kageyama; Danelle Eto; Tania C Escobar; Robert J Johnston; Laurel Monticelli; Christopher Lao; Shane Crotty
Journal:  Immunity       Date:  2011-06-24       Impact factor: 31.745

Review 2.  Antibiotics for inflammatory bowel disease: do they work?

Authors:  Mario Guslandi
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-02       Impact factor: 2.566

3.  Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.

Authors:  K Papp; D Thaçi; K Reich; E Riedl; R G Langley; J G Krueger; A B Gottlieb; H Nakagawa; E P Bowman; A Mehta; Q Li; Y Zhou; R Shames
Journal:  Br J Dermatol       Date:  2015-10-15       Impact factor: 9.302

4.  TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation.

Authors:  Trine Olsen; Renathe Rismo; Guanglin Cui; Rasmus Goll; Ingrid Christiansen; Jon Florholmen
Journal:  Cytokine       Date:  2011-09-25       Impact factor: 3.861

5.  Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease.

Authors:  Wenyu Jiang; Jiewen Su; Xiaofei Zhang; Xiuqin Cheng; Jun Zhou; Ruihua Shi; Hongjie Zhang
Journal:  Inflamm Res       Date:  2014-08-18       Impact factor: 4.575

6.  Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota.

Authors:  June L Round; Sarkis K Mazmanian
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

7.  A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Authors:  W Reinisch; D W Hommes; G Van Assche; J-F Colombel; J-P Gendre; B Oldenburg; A Teml; K Geboes; H Ding; L Zhang; M Tang; M Cheng; S J H van Deventer; P Rutgeerts; T Pearce
Journal:  Gut       Date:  2006-02-21       Impact factor: 23.059

8.  P-glycoprotein ABCB1: a major player in drug handling by mammals.

Authors:  Piet Borst; Alfred H Schinkel
Journal:  J Clin Invest       Date:  2013-10-01       Impact factor: 14.808

Review 9.  Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis.

Authors:  Ryan Ungaro; Charles N Bernstein; Richard Gearry; Anders Hviid; Kaija-Leena Kolho; Matthew P Kronman; Souradet Shaw; Herbert Van Kruiningen; Jean-Frédéric Colombel; Ashish Atreja
Journal:  Am J Gastroenterol       Date:  2014-09-16       Impact factor: 10.864

Review 10.  PU.1 and partners: regulation of haematopoietic stem cell fate in normal and malignant haematopoiesis.

Authors:  Pallavi Gupta; Gangenahalli U Gurudutta; Daman Saluja; Rajendra P Tripathi
Journal:  J Cell Mol Med       Date:  2009-04-06       Impact factor: 5.310

View more
  49 in total

1.  Interleukin-25 enhances the capacity of mesenchymal stem cells to induce intestinal epithelial cell regeneration.

Authors:  Jingling Su; Chenxi Xie; Yanyun Fan; Weizi Cheng; Yiqun Hu; Qingwen Huang; Huaxiu Shi; Lin Wang; Jianlin Ren
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  Smad nuclear interacting protein 1 (SNIP1) inhibits intestinal inflammation through regulation of epithelial barrier function.

Authors:  Y Shi; C He; C Ma; T Yu; Y Cong; W Cai; Z Liu
Journal:  Mucosal Immunol       Date:  2017-11-08       Impact factor: 7.313

3.  Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis.

Authors:  Marguerite S Buzza; Tierra A Johnson; Gregory D Conway; Erik W Martin; Subhradip Mukhopadhyay; Terez Shea-Donohue; Toni M Antalis
Journal:  J Biol Chem       Date:  2017-05-10       Impact factor: 5.157

4.  Colonoscopic-Guided Pinch Biopsies in Mice as a Useful Model for Evaluating the Roles of Host and Luminal Factors in Colonic Inflammation.

Authors:  David C Montrose; Xi K Zhou; Erin M McNally; Erika Sue; Hanhan Wang; Ryohei Nishiguchi; Akanksha Verma; Olivier Elemento; Kenneth W Simpson; Peiying Yang; Timothy Hla; Andrew J Dannenberg
Journal:  Am J Pathol       Date:  2018-09-28       Impact factor: 4.307

5.  A20 Restores Impaired Intestinal Permeability and Inhibits Th2 Response in Mice with Colitis.

Authors:  Donghui Chen; Li Ma; Tianyong Hu; Jiangqi Liu; Baohui Chen; Pingchang Yang; Zhiqiang Liu
Journal:  Dig Dis Sci       Date:  2019-10-04       Impact factor: 3.199

6.  Human dental follicle mesenchymal stem cells alleviate T cell response in inflamed tissue of Crohn's patients.

Authors:  Noushin Zibandeh; Deniz Genc; Yazgul Duran; Munhtsetseg Banzragch; Sakina Sokwala; Kamil Goker; Ozlen Atug; Tunç Akkoç
Journal:  Turk J Gastroenterol       Date:  2020-05       Impact factor: 1.852

7.  A Novel Fusion of IL-10 Engineered to Traffic across Intestinal Epithelium to Treat Colitis.

Authors:  Nicole C Fay; Baby-Periyanayaki Muthusamy; Linh P Nyugen; Radhika C Desai; Alistair Taverner; Julia MacKay; Minji Seung; Tom Hunter; Keyi Liu; Apurva Chandalia; Michael P Coyle; Hyojin L Kim; Sally Postlethwaite; Khushdeep Mangat; Lisa Song; Elbert Seto; Aatif Alam; Charles V Olson; Weijun Feng; Maziyar Saberi; Tahir A Mahmood; Randall J Mrsny
Journal:  J Immunol       Date:  2020-11-04       Impact factor: 5.422

8.  Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients.

Authors:  Yueying Chen; Hanyang Li; Qi Feng; Jun Shen
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

9.  Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora.

Authors:  Zhengjun Wang; Jinhua Chen; Zhiping Chen; Longke Xie; Wen Wang
Journal:  Saudi J Gastroenterol       Date:  2021 May-Jun       Impact factor: 2.485

10.  IL-1β pre-stimulation enhances the therapeutic effects of endometrial regenerative cells on experimental colitis.

Authors:  Dingding Yu; Yiming Zhao; Hongda Wang; Dejun Kong; Wang Jin; Yonghao Hu; Yafei Qin; Baoren Zhang; Xiang Li; Jingpeng Hao; Guangming Li; Hao Wang
Journal:  Stem Cell Res Ther       Date:  2021-06-05       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.